OBI-888 completes Phase I safety evaluation and demonstrates its safety and tolerability with no major concerns
Date of occurrence of the event: Jun 15, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Announcement of the company’s cash capital increase and base date
Date of occurrence of the event: Jun 14, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: N/A …
Board of directors of the company waived subscription rights exceeding half of the total subscribable shares. Shares to be subscribed by designated persons
Date of occurrence of the event: Jun 10, 2019 Reason for the forfeiture of subscription rights by the directors and supervisors: Overall investment strategy and financial planning considerations. Names of …
Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation
Date of occurrence of the event: May 06, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Supplementary announcement for the company to issue ordinary shares through rights offering
Date of the resolution by the board of directors or decision by the Company: Apr 18, 2019 Number of shares issued: 15,000,000 shares Par Value per share: NTD 10 Total …
Supplementary announcement for 2019 Annual General Meeting
Date of the board of directors resolution: Apr 19, 2019 Date for convening the shareholders’ meeting: Jun 27, 2019 Location for convening the shareholders’ meeting: Masterlink Securities Education and Training …
Announcement for the company to issue ordinary shares through rights offering and bank designated for collection and deposition
Date of the resolution by the board of directors or decision by the Company: Apr 18, 2019 Number of shares issued: 15,000,000 shares Par Value per share: NTD 10 Total …
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation
Date of occurrence of the event: Apr 12, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Announcement for the company to issue ordinary shares through rights offering
Date of the resolution by the board of directors or decision by the Company: Apr 09, 2019 Number of shares issued: 15,000,000 shares Par Value per share: NTD 10 Total …
OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999
Poster Presentations to highlight on mechanism of action, anti-tumor efficacy and pharmacokinetics profile for OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC) TAIPEI, Taiwan, March 28, 2019/OBI Pharma, Inc. …